Mark Cuban’s latest thought experiment starts where most AI debates end: with a pile of empty data centers and a lot of bruised egos. Instead of forecasting doom, he wonders whether an AI bust could become the most unexpected jobs program since…
In a world where investors handicap everything from rate cuts to chip cycles, a quieter thesis is gaining traction: exposure to actual trees may be as material to human performance as exposure to Treasury yields. A growing body of research in leading…
In a quarter where the market preferred flashy AI tickers to unglamorous healthcare plumbing, P3 Health Partners (PIII) and Amwell (AMWL) quietly reported results that suggest the real work in healthcare is happening far from meme stocks and momentum screens. Both companies…
Amwell’s (NYSE: AMWL) first-quarter scorecard reads like a classic Wall Street turnaround chapter: the top line is shrinking, but the balance sheet is fortified, losses are tightening, and management is whistling its way toward cash-flow breakeven by year-end.
Cash, Costs and a…
Amwell’s (NYSE: AMWL) latest story is a quiet telehealth turnaround: a company that spent the last cycle building infrastructure now talking more about operating leverage, sticky SaaS, and a disciplined path to growth – all while the rest of digital health is…